Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 8440 112 St. NW, Critical Care Medicine 2-124E Clinical Sciences Building, Edmonton, Alberta, T6G 2B7, Canada.
Alberta Strategy for Patient Oriented Research (SPOR) SUPPORT Unit-Knowledge Translation Platform, University of Alberta, 4-472 Edmonton Clinical Health Academy, 11405-87 Avenue, Edmonton, Alberta, T6G 1C9, Canada.
Crit Care. 2020 May 11;24(1):213. doi: 10.1186/s13054-020-2823-9.
Predicting successful liberation from mechanical ventilation (MV) in critically ill patients is challenging. Brain natriuretic peptide (BNP) has been proposed to help guide decision-making for readiness to liberate from MV following a spontaneous breathing trial (SBT).
We performed a systematic review and meta-analysis of randomized and prospective observational studies that measured BNP levels at the time of SBT in patients receiving MV. The primary endpoint was successful liberation from MV (absence of reintubation or non-invasive ventilation at 48 h). Statistical analyses included bi-variate and Moses-Littenberg models and DerSimonian-Laird pooling of areas under ROC curve (AUROC).
A total of 731 articles were screened. Eighteen adult and 2 pediatric studies were fulfilled pre-specified eligibility. The measure of the relative variation of BNP during SBT (ΔBNP%) after exclusion of SBT failure by clinical criteria in adults yielded a sensitivity and specificity of 0.889 [0.831-0.929] and 0.828 [0.730-0.896] for successful liberation from MV, respectively, with a pooled AUROC of 0.92 [0.88-0.97]. The pooled AUROC for any method of analysis for absolute variation of BNP (ΔBNP), pre-SBT BNP, and post-SBT BNP were 0.89 [0.83-0.95], 0.77 [0.63-0.91], and 0.85 [0.80-0.90], respectively.
The relative change in BNP during a SBT has potential value as an incremental tool after successful SBT to predict successful liberation from MV in adults. There is insufficient data to support the use of BNP in children or as an alternate test to clinical indices of SBT, or the use of ΔBNP, BNP-pre, and BNP-post as an alternate or incremental test.
PROSPERO CRD42018087474 (6 February 2018).
预测危重症患者机械通气(MV)成功撤离具有挑战性。脑利钠肽(BNP)已被提出用于指导在自主呼吸试验(SBT)后从 MV 撤离的决策。
我们对接受 MV 的患者在 SBT 时测量 BNP 水平的随机和前瞻性观察性研究进行了系统评价和荟萃分析。主要终点是 MV 成功撤离(48 小时内无再插管或无创通气)。统计分析包括双变量和摩西-李文伯格模型以及德西蒙-莱尔德汇总受试者工作特征曲线(ROC)下面积(AUROC)。
共筛选出 731 篇文章。18 项成人研究和 2 项儿科研究符合预定的纳入标准。在排除临床标准失败的 SBT 后,BNP 在 SBT 期间的相对变化(ΔBNP%)的测量成人 MV 成功撤离的敏感性和特异性分别为 0.889 [0.831-0.929] 和 0.828 [0.730-0.896],合并 AUROC 为 0.92 [0.88-0.97]。对于 BNP 的任何分析方法,绝对变化(ΔBNP)、SBT 前 BNP 和 SBT 后 BNP 的合并 AUROC 分别为 0.89 [0.83-0.95]、0.77 [0.63-0.91]和 0.85 [0.80-0.90]。
SBT 期间 BNP 的相对变化可能是成功 SBT 后预测成人 MV 成功撤离的附加工具。目前尚无足够的数据支持 BNP 在儿童中的应用,或作为 SBT 临床指标的替代试验,也没有数据支持 ΔBNP、BNP-pre 和 BNP-post 作为替代或附加试验。
PROSPERO CRD42018087474(2018 年 2 月 6 日)。